Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
Sign Up to like & getrecommendations! Published in 2020 at "Current problems in cancer"
DOI: 10.1016/j.currproblcancer.2020.100668
Abstract: INTRODUCTION Anaplastic thyroid carcinoma (ATC) is a highly aggressive, undifferentiated rare tumor. Median overall survival is usually between 8 and10 months, with a 1-year survival rate of 20%. Conventional anthracycline based chemotherapy regimens demonstrate low… read more here.
Keywords: anaplastic thyroid; dabrafenib; case; rechallenge ... See more keywords
Melanoma: Neo/adjuvant BRAF/MEKi improves outcomes
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/nrclinonc.2018.23
Abstract: Patients with stage III melanoma typically undergo surgery, followed by consideration for adjuvant therapy; however, only 30–50% of these patients are likely to survive >5 years after diagnosis. Now, the findings of a phase II… read more here.
Keywords: braf; group; improves outcomes; plus trametinib ... See more keywords
Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL)
Sign Up to like & getrecommendations! Published in 2022 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000837
Abstract: Efficacy and safety of dabrafenib and trametinib in metastatic melanoma have been demonstrated in two-phase III and one-phase I/II clinical trials. However, patients at least 75 years old (y.o.) were largely underrepresented. Additionally, the safety… read more here.
Keywords: safety; dabrafenib plus; braf v600; melanoma ... See more keywords
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.18.01219
Abstract: Purpose Dabrafenib plus trametinib improved relapse-free survival (RFS) versus placebo (hazard ratio [HR], 0.47; P < .001) in patients with resected BRAF V600–mutant stage III melanoma (BRF115532; COMBI-AD; ClinicalTrials.gov identifier: NCT01682083). We present an updated… read more here.
Keywords: free survival; relapse free; plus trametinib; dabrafenib plus ... See more keywords